These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10330953)

  • 1. Generic drugs: the Canadian perspective.
    McGilveray IJ; Gallicano K
    Transplant Proc; 1999 May; 31(3A Suppl):16S-18S. PubMed ID: 10330953
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic immunosuppressants: the European perspective.
    Christians U
    Transplant Proc; 1999 May; 31(3A Suppl):19S-22S. PubMed ID: 10330954
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioequivalence and generic prescribing: a pharmacy view.
    Calvert RT
    J Pharm Pharmacol; 1996 Jan; 48(1):9-10. PubMed ID: 8722486
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic HIV drugs--enlightened policy for global health.
    Wainberg MA
    N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804
    [No Abstract]   [Full Text] [Related]  

  • 6. [Special generic drugs in Spain].
    Carné X; Díez Rodrigálvarez M; García-Alonso F
    Med Clin (Barc); 1999 Mar; 112(9):337-9. PubMed ID: 10220766
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 8. [Input to the discussion on proposed regulation of prescription pharmacies].
    Agência Nacional de Vigilância Sanitária - Anvisa
    Rev Saude Publica; 2005 Aug; 39(4):691-4. PubMed ID: 16113925
    [No Abstract]   [Full Text] [Related]  

  • 9. Promise and Peril for Generic Drugs.
    Sharfstein JM; Greene J
    JAMA Intern Med; 2016 Jun; 176(6):733-4. PubMed ID: 27159885
    [No Abstract]   [Full Text] [Related]  

  • 10. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Endpoint Bioequivalence Studies Are Not Sensitive: A Perspective From Generic Drugs.
    Novakovic J; Szirtes J; Fields A; Tsang YC
    Clin Pharmacol Ther; 2019 Feb; 105(2):295-297. PubMed ID: 30456787
    [No Abstract]   [Full Text] [Related]  

  • 12. [Generic drugs in Brazil: historical overview and legislation].
    Araújo LU; Albuquerque KT; Kato KC; Silveira GS; Maciel NR; Spósito PÁ; Barcellos NM; Souza Jd; Bueno M; Storpirtis S
    Rev Panam Salud Publica; 2010 Dec; 28(6):480-92. PubMed ID: 21308175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of a generic phenytoin and Dilantin.
    Rosenbaum DH; Rowan AJ; Tuchman L; French JA
    Epilepsia; 1994; 35(3):656-60. PubMed ID: 8026413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
    Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
    Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotherapeutics in the era of biosimilars: what really matters is patient safety.
    Declerck PJ
    Drug Saf; 2007; 30(12):1087-92. PubMed ID: 18035862
    [No Abstract]   [Full Text] [Related]  

  • 16. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of generic drugs in Spain.
    García Alonso F
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():3. PubMed ID: 9800719
    [No Abstract]   [Full Text] [Related]  

  • 18. [Generic drug lines: all is not gold that glitters].
    Córdoba García R
    Aten Primaria; 1999 Oct; 24(7):387-9. PubMed ID: 10592545
    [No Abstract]   [Full Text] [Related]  

  • 19. Consideration of international generic distribution policies on patient outcomes in the United States and Germany.
    Saverno K; Gothe H; Schuessel K; Biskupiak J; Schulz M; Siebert U; Brixner D
    Pharmazie; 2014 Mar; 69(3):238-40. PubMed ID: 24716417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for generic anti-epileptic medicines: a regulatory perspective.
    Maliepaard M; Hekster YA; Kappelle A; van Puijenbroek EP; Elferink AJ; Welink J; Gispen-de Wied CC; Lekkerkerker FJ
    J Neurol; 2009 Dec; 256(12):1966-71. PubMed ID: 19603244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.